Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels
Open Access
- 7 September 2014
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 12 (11), 1788-1800
- https://doi.org/10.1111/jth.12723
Abstract
No abstract availableFunding Information
- Biogen Idec
This publication has 44 references indexed in Scilit:
- Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion proteinJournal of Thrombosis and Haemostasis, 2013
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood, 2012
- Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns surveyHaemophilia, 2012
- A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A managementJournal of Thrombosis and Haemostasis, 2012
- Up-regulation of platelet activation in hemophilia AHaematologica, 2011
- Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importanceHaemophilia, 2009
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- Clearance mechanisms of von Willebrand factor and factor VIIIJournal of Thrombosis and Haemostasis, 2007
- Practice patterns in haemophilia A therapy – global progress towards optimal careHaemophilia, 2006
- Barriers to compliance with prophylaxis therapy in haemophiliaHaemophilia, 2001